Walvax Biotechnology Co., Ltd. (300142.SZ)
CNY 10.47
(4.7%)
CNY 10.47
(4.7%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.74 Billion CNY | -13.08% |
| 2022 | 3.14 Billion CNY | 42.83% |
| 2021 | 2.2 Billion CNY | 45.07% |
| 2020 | 1.51 Billion CNY | 107.94% |
| 2019 | 729.93 Million CNY | 21.32% |
| 2018 | 601.68 Million CNY | 39.34% |
| 2017 | 431.8 Million CNY | 6.06% |
| 2016 | 407.11 Million CNY | -30.83% |
| 2015 | 588.58 Million CNY | 17.2% |
| 2014 | 502.22 Million CNY | 46.0% |
| 2013 | 343.98 Million CNY | 47.96% |
| 2012 | 232.48 Million CNY | 3.23% |
| 2011 | 225.21 Million CNY | 53.38% |
| 2010 | 146.83 Million CNY | 54.19% |
| 2009 | 95.23 Million CNY | -7.03% |
| 2008 | 102.43 Million CNY | 75.07% |
| 2007 | 58.51 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 509.32 Million CNY | 35.18% |
| 2024 Q3 | 419.97 Million CNY | -10.38% |
| 2024 Q1 | 376.76 Million CNY | -55.33% |
| 2023 Q2 | 720.8 Million CNY | 43.56% |
| 2023 Q1 | 502.09 Million CNY | -43.33% |
| 2023 Q3 | 616.44 Million CNY | -14.48% |
| 2023 Q4 | 843.45 Million CNY | 36.83% |
| 2023 FY | 2.73 Billion CNY | -13.08% |
| 2022 FY | 3.14 Billion CNY | 42.83% |
| 2022 Q1 | 420.61 Million CNY | -55.09% |
| 2022 Q3 | 868.98 Million CNY | -10.37% |
| 2022 Q2 | 969.57 Million CNY | 130.52% |
| 2022 Q4 | 886.05 Million CNY | 1.96% |
| 2021 Q4 | 936.52 Million CNY | 100.9% |
| 2021 Q1 | 264.4 Million CNY | -57.33% |
| 2021 Q2 | 534.91 Million CNY | 102.31% |
| 2021 Q3 | 466.16 Million CNY | -12.85% |
| 2021 FY | 2.2 Billion CNY | 45.07% |
| 2020 Q1 | 98.86 Million CNY | -60.2% |
| 2020 Q2 | 257.36 Million CNY | 160.31% |
| 2020 FY | 1.51 Billion CNY | 107.94% |
| 2020 Q3 | 541.97 Million CNY | 110.58% |
| 2020 Q4 | 619.63 Million CNY | 14.33% |
| 2019 Q2 | 185.37 Million CNY | 72.06% |
| 2019 FY | 729.93 Million CNY | 21.32% |
| 2019 Q1 | 107.73 Million CNY | -53.21% |
| 2019 Q3 | 188.41 Million CNY | 1.64% |
| 2019 Q4 | 248.4 Million CNY | 31.84% |
| 2018 Q1 | 82.04 Million CNY | -47.9% |
| 2018 FY | 601.68 Million CNY | 39.34% |
| 2018 Q3 | 127.71 Million CNY | -20.99% |
| 2018 Q4 | 230.27 Million CNY | 80.3% |
| 2018 Q2 | 161.64 Million CNY | 97.02% |
| 2017 Q3 | 105.64 Million CNY | 12.48% |
| 2017 FY | 431.8 Million CNY | 6.06% |
| 2017 Q1 | 74.74 Million CNY | -26.17% |
| 2017 Q2 | 93.92 Million CNY | 25.66% |
| 2017 Q4 | 157.47 Million CNY | 49.06% |
| 2016 Q3 | 122.6 Million CNY | 32.97% |
| 2016 FY | 407.11 Million CNY | -30.83% |
| 2016 Q1 | 91.06 Million CNY | -69.46% |
| 2016 Q4 | 101.23 Million CNY | -17.43% |
| 2016 Q2 | 92.2 Million CNY | 1.25% |
| 2015 Q2 | 89.3 Million CNY | -4.44% |
| 2015 FY | 588.58 Million CNY | 17.2% |
| 2015 Q4 | 298.2 Million CNY | 177.06% |
| 2015 Q3 | 107.63 Million CNY | 20.52% |
| 2015 Q1 | 93.45 Million CNY | -49.14% |
| 2014 Q1 | 96.8 Million CNY | -32.01% |
| 2014 Q2 | 91.68 Million CNY | -5.28% |
| 2014 Q3 | 129.99 Million CNY | 41.78% |
| 2014 Q4 | 183.72 Million CNY | 41.33% |
| 2014 FY | 502.22 Million CNY | 46.0% |
| 2013 Q1 | 60.76 Million CNY | -12.4% |
| 2013 Q2 | 42.38 Million CNY | -30.25% |
| 2013 Q3 | 98.44 Million CNY | 132.27% |
| 2013 Q4 | 142.38 Million CNY | 44.63% |
| 2013 FY | 343.98 Million CNY | 47.96% |
| 2012 Q2 | 65.08 Million CNY | 84.95% |
| 2012 Q1 | 35.19 Million CNY | -56.61% |
| 2012 FY | 232.48 Million CNY | 3.23% |
| 2012 Q4 | 69.37 Million CNY | 10.42% |
| 2012 Q3 | 62.83 Million CNY | -3.46% |
| 2011 Q3 | 56.01 Million CNY | -6.21% |
| 2011 Q4 | 81.11 Million CNY | 44.79% |
| 2011 Q1 | 28.35 Million CNY | -54.35% |
| 2011 FY | 225.21 Million CNY | 53.38% |
| 2011 Q2 | 59.72 Million CNY | 110.64% |
| 2010 Q2 | 30.78 Million CNY | 48.64% |
| 2010 FY | 146.83 Million CNY | 54.19% |
| 2010 Q4 | 62.11 Million CNY | 86.95% |
| 2010 Q3 | 33.22 Million CNY | 7.91% |
| 2010 Q1 | 20.71 Million CNY | 0.0% |
| 2009 FY | 95.23 Million CNY | -7.03% |
| 2008 FY | 102.43 Million CNY | 75.07% |
| 2007 FY | 58.51 Million CNY | 0.0% |